GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » Scaled Net Operating Assets

Organon (Organon) Scaled Net Operating Assets : 0.73 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Organon Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Organon's operating assets for the quarter that ended in Dec. 2023 was $11,365 Mil. Organon's operating liabilities for the quarter that ended in Dec. 2023 was $3,368 Mil. Organon's Total Assets for the quarter that ended in Sep. 2023 was $11,012 Mil. Therefore, Organon's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.73.


Organon Scaled Net Operating Assets Historical Data

The historical data trend for Organon's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Scaled Net Operating Assets Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial - 0.65 0.68 0.69 0.73

Organon Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.69 0.73 0.70 0.73

Competitive Comparison of Organon's Scaled Net Operating Assets

For the Drug Manufacturers - General subindustry, Organon's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organon's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organon's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Organon's Scaled Net Operating Assets falls into.



Organon Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Organon's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(11365-3368)/10955
=0.73

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=12058 - 693
=11365

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=12128 - 8751 - 9
=3368

Organon's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Sep. 2023 )
=(11365-3368)/11012
=0.73

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=12058 - 693
=11365

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=12128 - 8751 - 9
=3368

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Organon Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Organon's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Organon (Organon) Business Description

Traded in Other Exchanges
Address
30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada.
Executives
Kirke Weaver officer: Gen. Counsel & Corp. Secy. 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Ma. Fatima Francisco director ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Deborah H Telman officer: General Counsel 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathryn Dimarco officer: Corporate Controller 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Susanne Fiedler officer: Chief Commercial Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Vittorio Nisita officer: Head of Global Business Svcs 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Morrissey Joseph T. Jr. officer: Head of Manufacturing 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aaron Falcione officer: Chief Human Resources Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Deborah R Leone director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martha E Mcgarry director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Phillip Ozuah director 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Geralyn S Ritter officer: Hd of Ext. Affairs and ESG 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sandra Milligan officer: Head of Research & Development 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Cynthia M Patton director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Alan Ezekowitz director C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139